---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-312571"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2026-07-22T21:19:38+00:00"
generated_at: "2026-07-22T21:22:09.700442+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics prices upsized $375M public offering of 18.3M shares at $20.50/share

## Summary
- Offering of 18,300,000 shares at $20.50/share; gross proceeds $375.15M.
- Net proceeds estimated at $352.1M, or $405.0M if underwriters' option exercised.
- Underwriters granted 30-day option to purchase up to 2,745,000 additional shares.
- Closing expected July 23, 2026; proceeds extend cash runway into Q2 2028.
- Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James are joint book-runners.

## SEC filing metadata
- accession: 0001193125-26-312571
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2026-07-22T21:19:38+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/0001193125-26-312571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/d112911d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-312571
- JSON: https://secwatch.observer/filing/0001193125-26-312571.json
- Plain text: https://secwatch.observer/filing/0001193125-26-312571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.